A phase II study in recurrent or metastatic endometrial cancer utilizing the selective inhibitor of the EGF receptor (EGFR) tyrosine kinase activity erlotinib showed a low response rate of 12.5%, although it is well tolerated [107]. The gene discussed is EGFR; the disease is endometrial cancer.